DNA methylation of microRNA-375 in impaired glucose tolerance

Experimental and Therapeutic Medicine

Volumn 8, Issue 3, 2014, Pages 775-780

  Wang, Xiaoli ^a   Chang, Xiangyun ^a   Li, Jun ^a   Yin, Liang ^a   Sun, Kan ^a  

^a SHIHEZI UNIVERSITY   (China)

Author keywords

Impaired glucose tolerance; Methylation; miR 375; Type 2 diabetes

Indexed keywords

C PEPTIDE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; MICRORNA 375; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; CPG ISLAND; DIASTOLIC BLOOD PRESSURE; DNA METHYLATION; DOWN REGULATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN EXPRESSION; RNA ISOLATION; SYSTOLIC BLOOD PRESSURE; UPREGULATION; WAIST HIP RATIO;

EID: 84904396914     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.1816     Document Type: Article

References (30)

1. DeFronzo RA: Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58: 773-795, 2009.
2. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A and DeFronzo RA: β-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes mellitus: a new analysis. J Clin Endocrinol Metab 90: 493-500, 2005.
3. Abdul-Ghani MA, Tripathy D and DeFronzo RA: Contribution of β-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 29: 1130-1139, 2006.
4. Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D and DeFronzo RA: Insulin secretion and insulin action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes 55: 1430-1435, 2006.
5. Weyer C, Tataranni PA, Bogardus C and Pratley RE: Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 24: 89-94, 2001.
6. Jallut D, Golay A, Munger R, Frascarolo P, Schutz Y, Jéquier E and Felber JP: Impaired glucose tolerance and diabetes in obesity: a 6-year follow-up study of glucose metabolism. Metabolism 39: 1068-1075, 1990.
7. Altshuler D, Hirschhorn JN, Klannemark M, et al: The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26: 76-80, 2000.
8. Rissanen J, Markkanen A, Kärkkäinen P, et al: Sulfonylurea receptor 1 gene variants are associated with gestational diabetes and type 2 diabetes but not with altered secretion of insulin. Diabetes Care 23: 70-73, 2000.
9. Hara K, Okada T, Tobe K, et al: The Pro12Ala polymorphism in PPARγ2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commu 271: 212-216, 2000.
10. Chang TC and Mendell JT: microRNAs in vertebrate physiology and human disease. Annu Rev Genomics Hum Genet 8: 215-239, 2007.
11. Poy MN, Eliasson L, Krutzfeldt J, et al: A pancreatic islet-specific microRNA regulates insulin secretion. Nature 432: 226-230, 2004.
12. Baroukh N, Ravier MA, Loder MK, et al: MicroRNA-124a regulates Foxa2 expression and intracellular signaling in pancreatic β -cell lines. J Biol Chem 282: 19575-19588, 2007.
13. Joglekar MV, Parekh VS, Mehta S, Bhonde RR and Hardikar AA: MicroRNA profiling of developing and regenerating pancreas reveal post-transcriptional regulation of neurogenin3. Dev Biol 311: 603-612, 2007.
14. Plaisance V, Abderrahmani A, Perret-Menoud V, Jacquemin P, Lemaigre F and Regazzi R: MicroRNA-9 controls the expression of Granuphilin/Slp4 and the secretory response of insulin-producing cells. J Biol Chem 281: 26932-26942, 2006.
15. Tang X, Muniappan L, Tang G and Ozcan S: Identification of glucose-regulated miRNAs from pancreatic β cells reveals a role for miR-30d in insulin transcription. RNA 15: 287-293, 2009.
16. Lynn FC, Skewes-Cox P, Kosaka Y, McManus MT, Harfe BD and German MS: MicroRNA expression is required for pancreatic islet cell genesis in the mouse. Diabetes 56: 2938-2945, 2007.
17. Temple IK, Gardner RJ, Mackay DJ, Barber JC, Robinson DO and Shield JP: Transient neonatal diabetes: widening the understanding of the etiopathogenesis of diabetes. Diabetes 49: 1359-1366, 2000.
18. Report of a WHO Consultation: Definition, Diagnosis and Classification of Diabetes Mellitus and its complications: Report of a WHO Consultation 1999. Part 1: Diagnosis and classification of diabetes mellitus. pp1-65, 1999.
19. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001.
20. Poy MN, Hausser J, Trajkovski M, et al: miR-375 maintains normal pancreatic alpha-and beta-cell mass. Proc Natl Acad Sci USA 106: 5813-5818, 2009.
21. Xia HQ, Pan Y, Peng J and Lu GX: Over-expression of miR375 reduces glucose-induced insulin secretion in Nit-1 cells. Mol Bio Rep 38: 3061-3065, 2011.
22. El Ouaamari A, Baroukh N, Martens GA, Lebrun P, Pipeleers D and van Obberghen E: miR-375 targets 3'-phosphoinositide-dependent protein kinase-1 and regulates glucose-induced biological responses in pancreatic β-cells. Diabetes 57: 2708-2717, 2008.
23. de Souza Rocha Simonini P, Breiling A, Gupta N, et al: Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. Cancer Res 70: 9175-9184, 2010.
24. Ding L, Xu Y, Zhang W, et al: MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2.Cell Res 20: 784-793, 2010.
25. Sun K, Chang XY, Yin L, et al: Expression and DNA methylation status of microRNA-375 in patients with type 2 diabetes mellitus. Mol Med Rep 9: 967-972, 2014.
26. Reid G, Métivier R, Lin CY, et al: Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A. Oncogene 24: 4894-4907, 2005.
27. Kangaspeska S, Stride B, Métivier R, et al: Transient cyclical methylation of promoter DNA. Nature 452: 112-115, 2008.
28. Métivier R, Gallais R, Tiffoche C, et al: Cyclical DNA methylation of a transcriptionally active promoter. Nature 452: 45-50, 2008.
29. Maier S and Olek A: Diabetes: a candidate disease for efficient DNA methylation profiling. J Nutr 132 (Suppl 8): 2440S-2443S, 2002.
30. Barrès R, Osler ME, Yan J, et al: Non-CpG methylation of the PGC-1alpha promoter through DNMT3B controls mitochondrial density. Cell Metab 10: 189-198, 2009.